How Many People Work at Regenxbio? Headcount and Employee Trends

REGENXBIO Inc. is a biotechnology company developing adeno-associated virus (AAV) gene therapies and employs roughly 309 people. The organization has expanded its team with 18 new hires while 9 employees departed, reflecting measured, organic growth. Headcount data shows a balanced mix of scientific, technical, and corporate functions that support discovery, clinical development, and corporate operations. The workforce is concentrated in the Mid-Atlantic region, with additional staff classified as remote or other locations.

Engineering is the largest group at 85 employees, accounting for about one-quarter of the total workforce and underscoring the company’s focus on vector design and process development. Clinical and laboratory work is represented by 60 professionals in Healthcare roles, while Operations (47) and Business Management (34) provide manufacturing and administrative support. Finance & Administration (14), Quality (13), Marketing & Product (11), Program & Project Management (11), and Information Technology (10) round out the functional areas, with 24 employees categorized as Other specialized roles. Overall departmental data suggests a strong emphasis on R&D and technical execution balanced by the infrastructure needed to advance gene therapy programs.

REGENXBIO’s talent footprint is heavily rooted in the Maryland/DC biotechnology corridor. Washington, DC hosts 68 employees and nearby Rockville, MD—home to the company’s headquarters and manufacturing facility—employs 46. Additional clusters are found in Gaithersburg (18), Germantown (14), Frederick (9), Silver Spring (6), Bethesda (5), Laurel (5), and Baltimore (5), creating a network of sites within commuting distance of one another. A further 133 employees are listed under Other locations, indicating a blend of remote staff, field-based clinical personnel, or smaller satellite offices that extend the company’s reach beyond its primary hubs.